Get the latest news, insights, and market updates on ABOS (Acumen Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments
Acumen Pharmaceuticals (ABOS) recently dosed the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for sabirnetug, and also shared new Alzheimer’s research findings and upcoming recruitment plans. See our latest analysis for Acumen Pharmaceuticals. The recent clinical trial milestones appear to have coincided with strong momentum in the shares, with a 30.77% 1 day share price return, 46.24% 7 day share price return and a 70% 1 year total shareholder return, even... Jan 28, 2026 - $ABOS
Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS?
Acumen Pharmaceuticals recently reported that it has dosed the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for Alzheimer’s candidate sabirnetug, while its Chief Medical Officer and Chief Financial Officer sold shares to meet tax obligations from vested restricted stock units under pre-arranged plans. The combination of extending sabirnetug treatment for an additional 52 weeks and sharing fresh clinical findings and recruitment insights at an Alzheimer’s... Jan 26, 2026 - $ABOS
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
While mega-cap tech stocks with trillion-dollar valuations tend to dominate market headlines, they aren’t the only games in town. Smaller companies, especially those at the low end of the price spectrum, can offer meaningful upside. These are the so-called penny stocks – traditionally associated with shares trading for just pennies, but today defined more broadly as stocks priced below $5. At these low price levels, even small absolute price increases can translate into outsized percentage gains Jan 25, 2026 - $ABOS
January 2026's Rising Stars: Top Penny Stocks To Watch
As of January 2026, the U.S. stock market is experiencing some turbulence, with major indexes posting weekly losses amid rising Treasury yields and uncertainty surrounding Federal Reserve policies. In this context, penny stocks—though often considered a niche investment area—can still present intriguing opportunities for growth, particularly in smaller or newer companies with strong financial foundations. This article will explore three penny stocks that stand out for their balance sheet... Jan 19, 2026 - $ABOS
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching
The U.S. stock market has recently experienced a positive shift, with major indexes such as the Dow Jones and S&P 500 on track for their best week since June, following a brief trading halt due to technical issues. In this context of market recovery and optimism, investors may find value in exploring penny stocks—an investment area that still holds potential despite its somewhat outdated terminology. By focusing on smaller or newer companies with strong financial health, these stocks can... Nov 28, 2025 - $ABOS
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
NEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in people with early Alzheimer's disease. The open-label exte Nov 17, 2025 - $ABOS
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Cash, cash equivalents and marketable securities of $136.1 million as of Sept. 30, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast Nov 12, 2025 - $ABOS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple